kwinters71
Posted - 18 hours ago
$NVAX alright JJ, time to announce another $B deal with a BP
TickerDD_com
Posted - 23 hours ago
Play Stonk Trivia! 5 Strangest Market Events for $B and its company Barnes Group
https://youtu.be/33fE5nPsOAA
chromeal5
Posted - 1 day ago
$CATX F' what is wrong with you...C, Beatch. Woods is definitely in control, WHY?
While Likens just cashed out for a 1/2 $B ?
BioCrEq
Posted - 2 days ago
@Whtmtn shitcoins are trading in $B MC with better risk reward profile.. 🤷♂️
username_is_taken
Posted - 2 days ago
@DaveTrades it is not sustainable as is, the business will have to evolve at some point once Bitcoin is completely absorbed as a store of value by the world and it starts appreciating at roughly the average global gdp. I think the natural evolution will be to a finance company/ bank due to the massive amount of $b they are sitting on, they will need to generate a cash flow. In the medium turn just buying and holding can work out very well for them as the asset continues to rapidly appreciate.
InvestorBroGuy
Posted - 3 days ago
@UltraInstinct really wouldn’t be surprised to see $80s by early December. Really only takes a couple more macro sell offs coupled with some tax harvesting. Personally I’d love to see it as I’ve got some cash reserves ready to go and buying at an MC around $5B is one hell of a value considering there’s still half a $B left in share repurchases 🐊
uday817
Posted - 6 days ago
@StocktwitsIndia $B
Uppy
Posted - 1 week ago
$ELAB Nov 12 Forbes article on skin care - “Benjamin Button” like effects on skin. https://www.forbes.com/sites/jessicaourisman/2024/11/12/the-firsthand-results-of-a-nanofat-treatment-using-stem-cells-and-prp/
$ELAB weight loss - Ozempic competitor - this is a $B market
2 new patent filings
https://elevailabs.com/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-expands-patent-portfolio-with-two-new-filings-for-el-22-in-muscle-loss-treatment-for-obese-patients-including-glp-1-receptor-agonist-combinations/
May -acquired 2 exclusive patents
https://elevailabs.com/elevai-labs-acquires-exclusive-license-to-two-myostatin-muscle-loss-prevention-assets-with-plan-to-develop-in-combination-with-glp-1-obesity-treatments/
https://www.globenewswire.com/news-release/2024/10/21/2966100/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Highlights-Past-Positive-Preclinical-Data-Showing-Potential-of-EL-32-A-Dual-Myostatin-Activin-A-Blocker-For-the-Treatment-of-Obes.html
MarketMove
Posted - 1 week ago
$ALT imagine shorting like 30% of the shares of a biotech company in the weight loss / mash space with under a $B mcap
Kimdayz
Posted - 1 week ago
@Dazgard12 market cap double. Institutions are buying by the $B
IM_THE_BIG_GUY
Posted - 1 week ago
@PatientCap i think you are missing some $B for billions. but they should not use 100% of their own funds. actually think Gruber mentioned not using any Gevo equity.
artvandalay01
Posted - 1 week ago
Dude is worth a couple of $B probably programmed trade...
https://www.cnbc.com/2024/04/18/kam-ghaffarian-sets-his-sights-on-the-stars-with-space-companies.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
GoSoftlanding
Posted - 2 weeks ago
$B 44~47 solid.
bombastic_
Posted - 2 weeks ago
$LUNR is going further than $asts. It recently secured $B NASA contract
Quantumup
Posted - 2 weeks ago
Cantor Fitzgerald⬆️ $SRPT OW/$167 was Neutral/$152, says they would not be surprised to see $SRPT reit or⬆️'25 rev guide@an inv conf in early Jan—CF/many Analysts est sig growth4ELEVIDYS—LGMD not getting💳which could come fast/furious w/ some Accelerated Approvals: Baird⬇️➡️$193~thinks🚦cont2👉🏽2 multi-$B product:
GoSoftlanding
Posted - 2 weeks ago
$B I still like this chart..
Iman133
Posted - 2 weeks ago
$LXRX I hope you are ok :)
I am sure Trump will fix this corrupted market much better. Good thing is that we won’t see $B going to other countries
Phineas2
Posted - 2 weeks ago
@Coldbear It will take years, but IOVA is unlikely to do it alone. This is a potentially powerful platform, perhaps the best, and it will take 20-30 years to build out for all the solid mass cancers. That will require $B's, which leans toward a large biotech acquiring IOVA for the platform. Since checkpoint inhibitors should only boost results, it stands to reason that one of those companies should have the incentive to buy it. I do wish there was a lot more data, but at least insurance is paying for the therapies, and the company does not need to raise more capital, unless it wants to start other trials for other cancers.
Strategis
Posted - 2 weeks ago
$CORZ CoreWeave vs Equinix CoreWeave signed Msft in June 2023 and added Corz for 500MW.
CoreWeave will outgrow Equinix for revenue in less than 2 years. (Vs 10y for EQIX to reach $8B)
CoreWeave 2024 revenue $2B to 2.1 $B
CoreWeave 2025 revenue $8B (4x) estimate Equinix 10 years. 2014 revenue $2.44B
2024 revenue $8.6B (at 09/2024)
Nikki7220
Posted - 2 weeks ago
$ICU ***** Current SP is good for averaging down. Could be under 3 but it's a big plus for many still in buying. Short term in the pipeline to help SP would be news with data collected for the first 20-40 adult patients and a new partnership. WE ARE IN PHASE 3 !!! This phase usually a very strong candidate for a very strong partnership or takeover. However due to low OS shares, strong retail shareholders, low overhead expenses, forecasted in $B's in sales by CEO and revenue being generated from peds therefore takeover is unlikely but anything can happen.
jboii
Posted - 10/30/24
$XXII $CHUC $MO $PM Why hasn’t VLN taken off despite the FDA authorization? What’s holding it back? This company used to be in the $B’s.. what was so catastrophic?
blackberry123321
Posted - 10/30/24
$B face it, ladies and gentlemen, they have stolen our money
WhackaMole
Posted - 10/29/24
$MSTR As of Sept 20 MicroStrategy holds approximately 252,220 bitcoins worth roughly $17.6 billion. Average Cost is $39K or $9.9B so they have $B in profit. They issued $1B in Converts to pay of $500M in debt. Remaining $500M available to buy more BitCoint. Market cap is $50B! Underlying software business is worth $5B max. How can this valuation be sustained? What could they say on the earning call to justify a rally from here?
swingingtech
Posted - 10/28/24
$B $FLS $IR $PH
https://wallstreetwaves.com/barnes-group-reports-q3-earnings-below-expectations-despite-year-over-year-sales-growth/
DonCorleone77
Posted - 10/25/24
$B Barnes Group reports Q3 adjusted EPS 9c, consensus 39c Reports Q3 revenue $388M, consensus $380.31M. "In the third quarter, despite ongoing production delays from aircraft manufacturers, our Aerospace OEM business generated extraordinarily strong orders in anticipation of a future industry re-ramp. Meanwhile, our Aerospace aftermarket business continues to deliver robust performance on strong top-line growth. With the MB Aerospace integration and synergies progressing ahead of plan, we are delivering on our strategy to scale Aerospace and transform Barnes," said Thomas Hook, President and CEO of Barnes. "Over the last eighteen months, we have taken numerous actions to unlock the underlying value of Barnes by growing Aerospace, simplifying Industrial, investing in our businesses, and streamlining costs. Collectively, these actions have helped to position us for long-term profitable growth and led to outside interest in Barnes. As such, we are excited about our pending acquisition by Apollo Funds."
brs555
Posted - 10/23/24
$SGMO https://conf.sciencemate.com/c/prion2024 Getting past the BBB (blood brain barrier)is the game changer here. Most likely Fabry gets sold to highest bidder so Sandy and the team can focus on Neurology. Question is for how much? It will e a $B+ for sure JMHO
WeeklyTrader
Posted - 10/23/24
Falling knives with $B! RSI: 73.72% 50-day MA: $40.57 200-day MA: $37.99
gucag006
Posted - 1 month ago
$CORT My investment thesis on CORT is the following: 1) The revenue from Korlym is steadily increasing to about $0.5B in 2023 and highly profitable with free cash flow of $126M at the end of 2023, and there is no sign of letting in 2024; 2) Korlym is a difficult drug to administer since it adheres to three different receptors regulating three different hormones such that its addressable market is only about half of the Cushing Syndrome population; 3) The new drug, Relacorilant, with positive P3 data and ready for NDA anytime now, only adheres to a single receptor regulating cortisol, and much easier to administer than Korlym. Relacorilant with the entire Cushing Syndrome population as its addressable market. 4) CORT is simultaneously running another significant P2 and P3 clinical trials as shown below. Any of these, if successful, may add $B to its MC.
RaviDarji
Posted - 1 month ago
@StocktwitsIndia $B discount price
